EP Patent

EP3771715A1 — Crystalline forms of baricitinib

Assigned to Zaklady Farmaceutyczne Polpharma SA · Expires 2021-02-03 · 5y expired

What this patent protects

The invention relates to novel crystalline forms of baricitinib i.e. PPH form I and PPH form II and processes for preparation thereof. It also refers to pharmaceutical compositions containing said crystalline forms and to a use of said crystalline forms or pharmaceutical composit…

USPTO Abstract

The invention relates to novel crystalline forms of baricitinib i.e. PPH form I and PPH form II and processes for preparation thereof. It also refers to pharmaceutical compositions containing said crystalline forms and to a use of said crystalline forms or pharmaceutical compositions for the treatment of rheumatoid arthritis.

Drugs covered by this patent

Patent Metadata

Patent number
EP3771715A1
Jurisdiction
EP
Classification
—
Expires
2021-02-03
Drug substance claim
No
Drug product claim
No
Assignee
Zaklady Farmaceutyczne Polpharma SA
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.